Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes.

PLoS One · 2015 · PMC4636141 · PMID 26544192

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Percentage of time spent in target range (70–140 mg/dL) showed a trend toward an increase from baseline to end-of-treatment and a trend toward a decrease post-treatment, but this post-treatment decrease in time in target was significant only for the MDI subgroup.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.